# CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

> **NCT05260957** · PHASE2 · RECRUITING · sponsor: **Lazaros Lekakis** · enrollment: 22 (estimated)

## Conditions studied

- Refractory Non-Hodgkin Lymphoma
- Relapsed Non Hodgkin Lymphoma
- Aggressive Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Mosunetuzumab
- **DRUG:** Polatuzumab
- **BIOLOGICAL:** CAR-T Cell Therapy

## Key facts

- **NCT ID:** NCT05260957
- **Lead sponsor:** Lazaros Lekakis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-14
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05260957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05260957, "CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05260957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*